Display Settings:

Format

Send to:

Choose Destination
    J Psychiatry Neurosci. 2009 Mar;34(2):143-9.

    Glutamate and dopamine components in schizophrenia.

    Source

    Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada. philip.seeman@utoronto.ca

    Abstract

    The treatment of schizophrenia for the last half century has been with dopamine (DA) D(2) receptor blockers, implicating a hyperdopamine basis for psychosis. However, a 2007 report found that the glutamate agonist LY404039 was effective in schizophrenia, suggesting a hypoglutamate state for the illness. Although phencyclidine psychosis also supports a hypoglutamate cause, assessing the basic and clinical findings shows that phencyclidine has DA D(2) agonist actions as well. Accurate Dreiding models of phencyclidine and the LY glutamate agonists precisely fit the known tetrahedral model of the D(2) receptor that accommodates all DA agonists. A further view is that metabotropic glutamate agonists also exert D(2) agonism, and their antipsychotic doses (about 100 mg/d) are predicted by their dissociation constants (about 20 nM) for D(2). Hence, the clinical antipsychotic action of a glutamate agonist may depend on its ability to interfere with DA neurotransmission by its DA partial agonism.

    PMID:
    19270765
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2647567
    Free PMC Article

    Images from this publication.See all images (3) Free text

      Supplemental Content

      Icon for The Canadian Medical Association Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk